Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Grupo Español de Investigación en Cáncer de Ovario
Case Comprehensive Cancer Center
Beijing Biotech
University of California, Davis
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
The First Affiliated Hospital of Soochow University
Daiichi Sankyo
Imunon
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Imunon
Blue Earth Diagnostics
AbbVie
Myeloid Therapeutics
ARCAGY/ GINECO GROUP
Leiden University Medical Center
National Cancer Center, Korea
Incyte Corporation
Fundacion Clinic per a la Recerca Biomédica
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Baylor Research Institute
M.D. Anderson Cancer Center
AstraZeneca
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
RemeGen Co., Ltd.
Novartis
Shattuck Labs, Inc.
TORL Biotherapeutics, LLC
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Shanghai Gynecologic Oncology Group
Avenzo Therapeutics, Inc.
Institut Claudius Regaud
Oncology Institute of Southern Switzerland
Pfizer
MacroGenics
Amgen
AGO Research GmbH
Sutro Biopharma, Inc.
UNC Lineberger Comprehensive Cancer Center
National Cancer Center, Korea
Nurix Therapeutics, Inc.
AbbVie
Guardant Health, Inc.
Bicara Therapeutics
Massachusetts General Hospital
Xencor, Inc.
858 Therapeutics, Inc.